Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemarituzumab + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Bemarituzumab + CAPOX is a combination therapy consisting of bemarituzumab (a monoclonal antibody targeting FGFR2b), capecitabine (an oral prodrug of 5-fluorouracil), and oxaliplatin (a platinum-based alkylating agent). This regimen is under investigation for use in patients with previously untreated, advanced gastric or gastroesophageal junction cancer that overexpresses FGFR2b. Bemarituzumab inhibits FGFR2b signaling, thereby blocking tumor cell growth and survival in cancers overexpressing this receptor. Capecitabine is a chemotherapy agent that is metabolized to 5-fluorouracil, which interferes with DNA synthesis, while oxaliplatin forms DNA adducts that inhibit DNA replication and transcription[2][3].
- Brand names
- XelodaEloxatin
- Other names
- bemarituzumab + CAPOX
02
Targets
DNAFGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)TS (Thymidylate synthase)
Beyond the preview
Go deeper on bemarituzumab + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemarituzumab + capecitabine + oxaliplatin.